The LGALS2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from Raji cells, designed for loss-of-function studies of the LGALS2 gene. This product consists of a heterogeneous pool of cells harboring CRISPR/Cas9-mediated disruptions in the LGALS2 locus, providing a robust genetic background for functional analyses. The polyclonal format avoids clonal selection bias, making it suitable for population-level investigations of gene function in B lymphocyte models.
Raji cells are a human B lymphocyte line established from a Burkitt lymphoma patient and are characterized by Epstein-Barr virus (EBV) positivity and growth in suspension. These cells are widely employed in biomedical research to study antibody production, antigen presentation, and immune response regulation. Their malignant origin and EBV association make them particularly relevant for exploring mechanisms of lymphomagenesis and immune dysregulation.
The LGALS2 gene encodes galectin-2, a carbohydrate-binding protein that interacts with lymphotoxin alpha (LTA) and modulates NF-??B signaling. Galectin-2 functions downstream of TNF-?? and NF-??B and influences the extrinsic apoptotic pathway via regulation of caspase activation and Bcl-2 family proteins. Mechanistically, galectin-2 binding to LTA affects the IKK complex, driving I??B?? phosphorylation and NF-??B nuclear translocation, subsequently controlling expression of pro-inflammatory cytokines including IL-1?? and IL-6. Disruption of LGALS2 thereby perturbs these interconnected signaling cascades.
In Raji B cells, knockout of LGALS2 is anticipated to impair galectin-2-mediated regulation of T-cell apoptosis and inflammatory cytokine production, potentially altering B?CT cell interactions and NF-??B-dependent transcriptional programs. This cellular model is highly relevant for dissecting the molecular underpinnings of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, as well as inflammatory bowel disease and lymphoma, where dysregulated galectin-2 and NF-??B activity have been reported.
Researchers can utilize these polyclonal knockout cells in a wide array of experimental approaches. Western blotting and RT-qPCR enable confirmation of LGALS2 disruption and assessment of downstream gene expression changes. Flow cytometry facilitates profiling of cell surface markers and apoptosis assays (e.g., Annexin V staining) to evaluate programmed cell death. NF-??B reporter assays and cytokine ELISAs provide quantitative readouts of signaling pathway activity. Co-immunoprecipitation experiments can probe altered protein interactions, particularly with LTA and glycoprotein ligands. These applications support in-depth investigations of B cell biology, inflammation, and lymphoma pathogenesis. For further information, please contact Ascent Research.
